Prexige TARGET Study: Not Quite A Bull’s-Eye For Novartis
Executive Summary
Novartis' TARGET study found that the COX-2 inhibitor Prexige has approximately one-third the rate of gastrointestinal side effects compared to non-steroidal anti-inflammatory drugs
You may also be interested in...
Novartis Is Confident In Prexige’s Prospects Despite Arcoxia AC Debacle
Novartis is confident its COX-2 inhibitor Prexige does not raise the same safety concerns cited by an FDA advisory committee in recommending against approval of Merck's COX-2 agent Arcoxia
Novartis Is Confident In Prexige’s Prospects Despite Arcoxia AC Debacle
Novartis is confident its COX-2 inhibitor Prexige does not raise the same safety concerns cited by an FDA advisory committee in recommending against approval of Merck's COX-2 agent Arcoxia
Prexige Still Postponed: Novartis To Resubmit COX-2 Inhibitor In U.S. In 2007
Novartis plans to resubmit Prexige (lumiracoxib) in the U.S. in the first half of 2007; approval of the oral COX-2 inhibitor in the European Union and Canada for treatment of osteoarthritis symptoms was announced Nov. 7